Clinical Trials Logo
  1. Home
  2. Cytomegalovirus (CMV)
  3. NCT02775240

Study of SHP620 (Maribavir) in Healthy Adults

Cytomegalovirus (CMV) Clinical Trial

Official title:
A Phase 1, Open-label, 2-period Fixed-sequence Study to Evaluate the Effect of Multiple Doses of SHP620 (Maribavir) on the Pharmacokinetics of Digoxin and Dextromethorphan in Healthy Adult Subjects

Clinical Trial Summary

The purpose of this study is to determine how an investigational treatment (maribavir) is handled by the body when administered with two already approved drugs (digoxin and dextromethorphan). The study will also look at the safety and tolerability when maribavir is coadministered with digoxin and dextromethorphan versus digoxin and dextromethorphan alone.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02775240
Study type Interventional
Source Takeda
Contact
Status Completed
Phase Phase 1
Start date July 21, 2016
Completion date September 12, 2016
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05319353 - A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Children and Teenage Transplant Recipients With CMV Infection Phase 3
Completed NCT05571137 - A Study on Cytomegalovirus (CMV) Infection Outcomes Among Hematopoietic Stem Cell Transplant (HSCT) Participants in Europe and Canada
Not yet recruiting NCT06243731 - A Study of Maribavir in Adults With Kidney Failure Who Have a Cytomegalovirus (CMV) Infection After Transplantation
Completed NCT05576805 - A Study on Cytomegalovirus (CMV) Infection Outcomes Among Solid Organ Transplant (SOT) Participants in Europe and Canada
Not yet recruiting NCT06213974 - A Study of Maribavir in Adults With Post-transplant Cytomegalovirus (CMV) Infection in Argentina
Completed NCT01611974 - Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients Phase 2
Completed NCT05137717 - A Study of Maribavir in Japanese People With Cytomegalovirus (CMV) Infection Phase 3
Completed NCT02931539 - Efficacy and Safety Study of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir Phase 3
Completed NCT02927067 - A Study of Maribavir Compared to Valganciclovir to Treat Cytomegalovirus Infections in People Who Have Received Stem Cell Transplants Phase 3